ERBB2 and neoplasm: Interestingly, however, clinical trials applying the preconditioning strategy using HER-2, CEA, WT1, MAGE2, and Survivin antigen-overexpressing apoptotic tumor cells did not show comparable efficiency in lung cancer patients, raising the question of whether implementation of the use of DCs can deliver similar clinical advantages in distinct cancer types [119].